---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-131792"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:27:21.856188+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexeo reports FY2025 net loss $100M; cash $246.6M, runway into 2028; LX2006 pivotal trial on track for 1H2026

## Summary
- Net loss FY2025 $100.0M ($1.86/share) vs $98.3M ($3.09/share) in FY2024; Q4 loss $20.9M ($0.27).
- R&D expenses FY2025 $63.8M vs $74.1M in FY2024; G&A $45.5M vs $31.7M.
- Cash $246.6M as of Dec 31, 2025, expected to fund operations into 2028.
- LX2006 for FA: FDA feedback on SUNRISE-FA 2 pivotal protocol expected Q2 2026; trial start 1H 2026.
- Collaboration with Johnson & Johnson for targeted cardiac AAV delivery; new CMO Dr. Narinder Bhalla appointed.

## SEC filing metadata
- accession: 0001193125-26-131792
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000119312526131792/0001193125-26-131792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000119312526131792/lxeo-20260330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-131792
- JSON: https://secwatch.observer/filing/0001193125-26-131792.json
- Plain text: https://secwatch.observer/filing/0001193125-26-131792.txt

## Key facts
- Earnings Releases
  Lexeo Therapeutics, Inc. reported financial results for the fourth quarter and full year 2025.
  - Period: the fourth quarter and full year 2025
  - Result: reported results
  source text: On March 30, 2026, Lexeo Therapeutics, Inc. (the “ Company ”) issued a press release announcing business highlights and its financial results for the three and twelve months ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907108/000119312526131792/0001193125-26-131792-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.